+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetes Care Intelligence Center 2012-2023

  • ID: 4757852
  • Report
  • Mordor Intelligence
1 of 5

FEATURED COMPANIES

  • Abbott Diabetes Care
  • Ascensia Diabetes Care
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Merck and Co.
  • Roche
  • MORE

The Diabetes Care Intelligence Center (IC) is a global intelligence database on diabetes drugs & devices, which offers data on 25 major countries. It covers 13 years of comparable data, including 5-year forecasts incorporating value, volume sales, and price and price per-capita expenditure. The Intelligence Centre enhances your understanding of the diabetes drugs industry, along with economic factors impacting diabetes drug usage, such as diabetes population, Type 1 and Type 2 Diabetic population, and obesity, which provide you with actionable business insights.

Market Scope

  • Diabetes drugs & devices market data, volume and value analytics with growth trends (2012-2023)
  • Branded & generic drugs and devices’ sales data from 2012-2023
  • Segment, sub-segment & company devices’ sales data from 2012-2023
  • Additional information includes – diabetic population levels, diabetes prevalence, Diabetes Type 1 population, Diabetes Type 2 population, and per-capita expenditure.

The Diabetes Care Intelligence Center provides exhaustive coverage (countries covered account for more than 80% of the overall spending on diabetes). Covering and tracking of over 18,000 data points of the diabetes drugs industry, which covers various categories, segments, Active Pharmaceutical Ingredients (APIs), and brands. It also covers more than 8,000 data points of the diabetes care device market, which encompass various categories, segments, sub-segments and company share analysis.

Diabetes Drug Categories:

  • Insulin
  • Basal Insulin or Long-acting Insulin
  • Bolus Insulin or Fast-acting Insulin
  • Pre-mixed Insulin or Combination Insulin
  • Traditional Human Insulins
  • Traditional Human Insulin Biosimilars
  • Insulin Glargine Biosimilars
  • Non-Insulin Injectable
  • GLP-1 Agonist Market
  • Amylin Analogue
  • Oral Anti-diabetics Drugs
  • Dopamine-D2 Receptor Agonist
  • Meglitinide
  • Alpha-Glucosidase Inhibitors
  • SGLT2 Inhibitors
  • Biguanides
  • Sulfonylureas
  • DPP-4 Inhibitors
  • Combination Drugs
  • Insulin Combinations
  • Oral Combinations
  • Diabetes Device Categories
  • Management Devices
  • Insulin-delivery Devices
  • Insulin Syringes
  • Cartridges in Reusable Pens
  • Disposable Pens
  • Jet Injectors
  • Insulin Pump
  • Insulin Pump Devices
  • Insulin Pump Reservoirs
  • Infusion Sets
  • Monitoring Devices
  • Self-monitoring Blood Glucose Devices (SMBG)

By Component:

  • Glucometer Devices
  • Test Strips
  • Lancets
  • By End-user
  • Hospital
  • Glucometer Devices
  • Test Strips
  • Lancets
  • Personal
  • Glucometer Devices
  • Test Strips
  • Lancets
  • Continuous Glucose Monitoring Devices (CGM)
  • CGM durables (Receivers and Transmitters)
  • Sensors

Market Overview

The global diabetes care market is expected to grow because of the growing diabetes population levels and increasing diabetes expenditure in established, as well as pharm emerging countries.

Global Rise in Diabetic Population

  • There has been a tremendous increase in the global diabetic population levels over the past decade. Several reports and surveys documented a drastic increase in the diabetic population levels, based on the changing lifestyles and habits.
  • Extensive urbanization in various parts of the globe is considered to be the primary cause of obesity, health deterioration, physical inactivity, etc. Owing to these factors the prevalence of Type 2 Diabetes mellitus (T2DM) has increased significantly.
  • It is estimated that out of the total 415 million people suffering from diabetes worldwide, 46% of this demographic is those with undiagnosed diabetes.
  • The growing diabetic population levels act as a driver for insulin monitoring devices, such as glucometers, CGMs, etc. In developed countries, close to 90% of Type 1 Diabetic patients use glucometers. It is expected that during the forecast period close to 50% of Type 2 Diabetic patients will use a glucometer.

The United States Leads the Diabetes Drugs & Devices Market 

  • In 2017, the US diabetes drugs market held the largest market share in North America, due to the presence of a high-quality healthcare system and increasing prevalence of diabetes in the region.
  • In the Asia-Pacific region, China and India have been identified as potential emerging markets, due to the rising diabetic population levels.

Reasons to Purchase this Dashboard

  • More Granular: Covers more categories, segments and brands’ information at country- and global-levels compared to other market intelligence providers
  • Analyzing the outlook of the market with recent market data, historical data and market forecast
  • Ease of Comparability: Analytics are based on a standardized definition across the globe to facilitate better comparability of market data
  • View the market in different ways among categories and geography to understand where actual opportunities lie
  • Market segmentation including quantitative research, incorporating the impact of economic and non-economic aspects
  • Regional- and country-level data integrating the demand and supply forces which are influencing the growth of the market
  • Market value (in USD million) and volume data for each segment and sub-segment
  • Understanding of the market based on value and volume changes, intra category competition.
  • Dedicated analyst support for research queries and training
  • Continuous yearly amendment of the database with significant changes updated based on scenarios

Countries covered:

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Mexico
  • Brazil
  • Japan
  • South Korea
  • China
  • India
  • Australia
  • Vietnam
  • Malaysia
  • Indonesia
  • Philippines
  • Thailand
  • Saudi Arabia
  • Iran
  • Egypt
  • Oman
  • South Africa

Customization of the Dashboard

This dashboard can be customized to meet your requirements by adding the country of your choice and qualitative trends on request. Please connect with our Customer Service team, who will assist to get a dashboard that suits your needs.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Diabetes Care
  • Ascensia Diabetes Care
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Merck and Co.
  • Roche
  • MORE

1. Introduction

1.1 Key Deliverables of the Study

1.2 Market Definition

2. Research Approach and Methodology

2.1 Introduction

2.2 Research Designs

2.3 Study Phases

2.3.1 Internal Sources Evaluation

2.3.2 Research Process

2.3.3 Modeling & Triangulation

2.3.4 Data Finalization

2.3.5 Expert Validation

3. Market Segmentation

3.1 By Drug

3.1.1 Oral Anti-diabetic drugs

3.1.1.1 Biguanide 

3.1.1.1.1 Metformin

3.1.1.2 Alpha - Glucosidase Inhibitors 

3.1.1.2.1 Alpha - Glucosidase Inhibitors

3.1.1.3 Dopamine -D2 Receptor Agonist 

3.1.1.3.1 Bromocriptin (Cycloset)

3.1.1.4 Sodium - Glucose Cotransport - 2 (SGLT-2) Inhibitor 

3.1.1.4.1 Invokana (Canagliflozin)

3.1.1.4.2 Jardiance (Empagliflozin)

3.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

3.1.1.4.4 Suglat (Ipragliflozin)

3.1.1.5 Dipeptidyl peptidase - 4 (DPP-4) inhibitors 

3.1.1.5.1 Januvia (Sitagliptin)

3.1.1.5.2 Onglyza (Saxagliptin)

3.1.1.5.3 Tradjenta (Linagliptin)

3.1.1.5.4 Vipidia/Nesina (Alogliptin)

3.1.1.5.5 Galvus (Vildagliptin)

3.1.1.6 Sulfonylureas 

3.1.1.6.1 Sulfonylureas

3.1.1.7 Meglitinide 

3.1.1.7.1 Meglitinide

3.1.2 Insulin

3.1.2.1 Basal or Long-acting Insulins

3.1.2.1.1 Lantus (Insulin Glargine)

3.1.2.1.2 Levemir (Insulin Detemir)

3.1.2.1.3 Toujeo (Insulin Glargine)

3.1.2.1.4 Tresiba (Insulin Degludec)

3.1.2.1.5 Basaglar (Insulin Glargine)

3.1.2.2 Bolus or Fast Acting Insulins

3.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

3.1.2.2.2 Humalog (Insulin Lispro)

3.1.2.2.3 Apidra (Insulin Glulisine)

3.1.2.3 Traditional Human Insulins

3.1.2.3.1 Novolin/Actrapid/Insulatard

3.1.2.3.2 Humilin

3.1.2.3.3 Insuman

3.1.2.4 Biosimilar Insulins

3.1.2.4.1 Insulin Glargine Biosimilars

3.1.2.4.2 Human Insulin Biosimilars

3.1.3 Non-Insulin Injectable Drugs

3.1.3.1 GLP1 Receptor Agonists

3.1.3.1.1 Victoza (Liraglutide)

3.1.3.1.2 Byetta (Exenatide)

3.1.3.1.3 Bydureon (Exenatide)

3.1.3.1.4 Trulicity (Dulaglutide)

3.1.3.1.5 Lyxumia (Lixisenatide)

3.1.3.2 Amylin Analogue

3.1.3.2.1 Symlin (Pramlintide)

3.1.4 Combination Drugs

3.1.4.1 Insulin Combinations

3.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

3.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

3.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

3.1.4.2 Oral Combination

3.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

3.2 By Device

3.2.1 Monitoring Devices

3.2.1.1 Self-monitoring Blood Glucose Devices

3.2.1.1.1 By Component 

3.2.1.1.1.1 Glucometer Devices

3.2.1.1.1.2 Test Strips

3.2.1.1.1.3 Lancets 

3.2.1.1.2 By End User

3.2.1.1.2.1 Hospital 

3.2.1.1.2.1.1 Glucometer Devices

3.2.1.1.2.1.2 Test Strips

3.2.1.1.2.1.3 Lancets

3.2.1.1.2.2 Personal 

3.2.1.1.2.2.1 Glucometer Devices

3.2.1.1.2.2.2 Test Strips

3.2.1.1.2.2.3 Lancets

3.2.1.2 Continuous Blood Glucose Monitoring

3.2.1.2.1 By Component 

3.2.1.2.1.1 Sensors

3.2.1.2.1.2 Receivers

3.2.2 Management Devices

3.2.2.1 Insulin Pump

3.2.2.1.1 Insulin Pump Device

3.2.2.1.2 Insulin Pump Reservoir

3.2.2.1.3 Infusion Set

3.2.2.2 Insulin Syringes

3.2.2.3 Insulin Cartridges 

3.2.2.4 Disposable Pens

3.2.2.5 Jet Injectors

3.3 Geography

3.3.1 North America

3.3.1.1 United States 

3.3.1.2 Canada 

3.3.1.3 Rest of North America 

3.3.2 Europe

3.3.2.1 France 

3.3.2.2 Germany 

3.3.2.3 Italy 

3.3.2.4 Spain 

3.3.2.5 United Kingdom 

3.3.2.6 Russia 

3.3.2.7 Rest of Europe 

3.3.3 Latin America

3.3.3.1 Mexico 

3.3.3.2 Brazil 

3.3.3.3 Rest of Latin America 

3.3.4 Asia-Pacific

3.3.4.1 Japan 

3.3.4.2 South Korea 

3.3.4.3 China 

3.3.4.4 India 

3.3.4.5 Australia 

3.3.4.6 Vietnam 

3.3.4.7 Malaysia 

3.3.4.8 Indonesia 

3.3.4.9 Philippines 

3.3.4.10 Thailand 

3.3.4.11 Rest of Asia Pacific 

3.3.5 Middle East & Africa

3.3.5.1 Saudi Arabia 

3.3.5.2 Iran 

3.3.5.3 Egypt 

3.3.5.4 Oman 

3.3.5.5 South Africa 

3.3.5.6 Rest of Middle & Africa 

4. Market Indicators

4.1 Type-1 Diabetes Population (2012-2023)

4.2 Type-2 Diabetes Population (2012-2023)

5. Company Share Analysis

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Diabetes Care
  • Acon
  • Agamatrix Inc.
  • Arkray
  • Ascensia Diabetes Care
  • Astellas
  • AstraZeneca
  • Bionime Corporation
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dexcom
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • Medisana
  • Medtronic
  • Merck and Co.
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Rossmax
  • Sanofi
  • Takeda
  • Trivida
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4757852
Adroll
adroll